{
    "nct_id": "NCT03190278",
    "official_title": "Phase I, Open Label Dose Escalation and Dose-Expansion Study to Evaluate the Safety, Expansion, Persistence, and Clinical Activity of UCART123 (Allogeneic Engineered T-cells Expressing Anti-CD123 Chimeric Antigen Receptor), Administered in Patients With Relapsed/Refractory Acute Myeloid Leukemia",
    "inclusion_criteria": "* Patients with relapsed or primary refractory AML (as defined in World Health Organization [WHO] criteria) with ≥5% bone marrow blasts\n* Patients with CD123+ blast cells (verified by flow cytometry)\n* Eastern Cooperative Oncology Group Performance Status (ECOG-PS) of ≤1\n* Adequate organ function, including bone marrow, renal, hepatic, pulmonary, and cardiac function based on the last assessment performed within screening period\n* (Dose-escalation) Identified donor and transplant strategy prior to lymphodepletion (LD)\n* Other criteria may apply\n\nMain\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 65 Years",
    "exclusion_criteria": "* Patients with acute promyelocytic leukemia (APL) or central nervous system (CNS) Leukemia\n* Previous investigation gene or cell therapy (including CAR)\n* > 1 prior allogeneic stem cell transplantations (SCTs)\n* Prior treatment with rituximab or other anti-cluster of differentiation 20 (anti-CD20) therapy within 3 months\n* Any known active or uncontrolled infection\n* Other criteria may apply",
    "miscellaneous_criteria": "Main"
}